GT Biopharma Inc is a biotechnology company focused on developing innovative immuno-oncology therapies to treat various forms of cancer. The company specializes in harnessing the power of the immune system to identify and destroy cancer cells through its proprietary platforms, which include novel antibody constructs and immune cell engineering. By advancing its therapeutic candidates through clinical trials, GT Biopharma aims to improve treatment outcomes for patients suffering from solid tumors and hematological malignancies. Through strategic partnerships and cutting-edge research, the company is dedicated to addressing unmet medical needs in the oncology space. Read More
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
GT Biopharma's Phase 1 trial of GTB-3650 progresses with early safety signals, immune activation, and plans to advance to higher dose cohorts into 2026.
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
GTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing potential for NK cell expansion and increased immunologic activity. Detailed results to be released in 2025. GTBP stock up 0.90%.
The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.
